U.S. Markets open in 2 hrs 24 mins

Bragar Eagel & Squire is Investigating Certain Officers and Directors of PriceSmart, Pyxus, Aclaris Therapeutics, and Zimmer Biomet Holdings and Encourages Investors to Contact the Firm

NEW YORK, Oct. 06, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire is investigating certain officers and directors of PriceSmart, Inc. (PSMT), Pyxus International, Inc. (PYX), Aclaris Therapeutics, Inc. (ACRS), and Zimmer Biomet Holdings, Inc. (ZBH) on behalf of long-term stockholders.  More information about each potential case can be found at the link provided.

PriceSmart, Inc. (PSMT)

Bragar Eagel and Squire is investigating certain officers and directors of PriceSmart, Inc. following a class action complaint that was filed against PriceSmart May 22, 2019.

The complaint filed alleges that throughout the class period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the company’s omni-channel business strategy had failed to reach key operating goals; (2) that the company’s South America distribution strategy had failed to realize key cost saving goals; (3) that the company had invested Trinidad and Tobago dollars into certificates of deposits with financial institutions; (4) that these investments had been improperly classified as cash and cash equivalents; (5) that the relevant corrections would materially impact financial statements; (6) that there was a material weakness in the company’s internal controls over financial reporting; (7) that increasing competition negatively impacted the company’s revenue and profitability; and (8) that, as a result of the foregoing, Defendants positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on our investigation into PriceSmart, go to: https://bespc.com/PSMT

Pyxus International, Inc. (PYX)

Bragar Eagel & Squire is investigating Pyxus International, Inc. following a class action complaint that was filed against Pyxus on June 7, 2019.

The complaint alleges that throughout the class period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the company was experiencing longer shipping cycles; (2) that, as a result, the company’s financial results would be materially affected; (3) that the company lacked adequate internal control over financial reporting; (4) that the company’s accounting policies were reasonably likely to lead to regulatory scrutiny; and (5) that, as a result of the foregoing, defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on our investigation into Pyxus go to: https://bespc.com/pyx

Aclaris Therapeutics, Inc. (ACRS)

Bragar Eagel & Squire is investigating certain officers and directors of Aclaris Therapeutics, Inc. following a class action complaint that was filed against Aclaris on July 30, 2019.

The complaint alleges that throughout the class period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the company’s advertising materials minimized the risks and overstated the efficacy of ESKATA to generate sales; (2) that, as a result, the company was reasonably likely to face regulatory scrutiny; and (3) that, as a result of the foregoing, defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on our investigation into Aclaris go to: https://bespc.com/acrs

Zimmer Biomet Holdings, Inc. (ZBH)

Bragar Eagel & Squire is investigating certain officers and directors of Zimmer Biomet Holdings following an amended class action complaint that was filed on March 21, 2019.

The complaint alleges that defendants issued a series of material misstatements and omissions to investors regarding, among other things, (1) Zimmer’s discovery of wide-ranging “systemic issues” with the quality system at the primary Legacy Biomet manufacturing facility in Warsaw; (2) Zimmer’s failure to take prompt and necessary actions to remediate these issues fully; and (3) Zimmer’s inability to simultaneously satisfy the demand for its products while remediating these issues.

For more information on our investigation into Zimmer go to: https://bespc.com/zbh

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes. 

Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com